Product Development

There is an urgent global need for new influenza therapeutics to save lives during seasonal influenza infections and to prepare for pandemic influenza. Gemmus Pharma is preparing to file an investigational new drug (IND) application with the FDA and is planning a Phase 2 clinical study of its lead candidate, GP1001.

Profile of lead candidate, GP1001

Orally-available, non-peptidic eiconsanoid analog
Efficacious in Animal Models (See completed studies)
Clinically established Safety Profile
Realistic CMC

Gemmus Pharma Technology

Technology Background
Gemmus Pharma Approach
Market Opportunities
Company Brochure